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Introduction 
The thyroid transcription factor 1 (TTF-1) is a protein
belonging to the homeobox-containing gene family.
This kind of protein plays very important roles in
development, cell growth and differentiation processes
[1]. TTF-1 is required for expression of the thyroid
stimulating hormone receptor gene in thyroid cells and
essential for the morphogenesis of the thyroid, lung
and ventral forebrain [2]. 
One of the most important factors evaluating the
biological aggressiveness of carcinoma is the cell pro-
liferating activity. The presence of Ki-67, a nuclear
protein expressed in all human proliferating cells
except when they are at the G0 phase, has not been
well studied in thyroid cancers. Anaplastic thyroid
cancer (ATC) is a highly aggressive neoplasm and sur-
gery is often not possible due to the involvement of
vital structures in the neck. The survival of patients
with ATC tends to be a matter of months, despite
aggressive use of various therapeutic modalities. 
The anaplastic transformation, or the intratumoral
evolution of anaplastic carcinoma from pre-existing
well differentiated thyroid cancer (WDC) has been
described in several publications [3,4]. The possibili-
ty that well differentiated thyroid carcinoma can
evolve into anaplastic thyroid carcinomas has partic-
ular importance in the prognosis and therapeutic
approach to the management of thyroid neoplasm. In
the presented report we intend to demonstrate the
purposefulness of TTF-1 and Ki-67 immunocyto-
chemical marker application as helpful in diagnosis
and discrimination of the two different types of thy-
roid carcinomas. 
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Abstract: We report the immunohistochemical diagnosis, including TTF-1 (thyroid transcription factor 1) and Ki-67, of a
rare mixed thyroid neoplasm composed of minimally invasive well differentiated follicular areas and highly aggressive
undifferentiated anaplastic areas. A 75 old female presented to our clinic with a rapidly growing neck mass. Considering the
dynamics of the disease and the multiple challenges presented by the patient: advanced age, tumor size, history of a long-
standing goiter we decided to transfer her to the department of surgery. The intraoperative findings were an enlarged right
lobe with tracheal and surrounding tissues infiltration. Total thyroidectomy, radical neck lymph nodes dissection and tra-
cheostomy were performed. The histopathological and immunohistochemical examination revealed a coexistent anaplastic
and follicular thyroid carcinoma. The proliferation index Ki-67, a cell proliferation marker, was found to be significantly
higher in the anaplastic areas (30 ± 5%) in the comparison with the follicular areas (2 ± 1%). The evaluation of the thyroid
transcription factor 1 (TTF-1) expression revealed a correlation with the tumor cells aggressiveness accordingly to the can-
cer areas. After a radical surgery an external adjuvant radiation was applied. The patient is alive and more than five years
after diagnosis she presented an increase of the serum thyroglobulin level suggesting, probably, a recurrence of the follicu-
lar form of the cancer. According to our survey we suggest that in thyroid cancers TTF-1 and Ki-67 could provides useful
information on the differentiation activities of thyroid tumor cells and may be helpful to distinguish well differentiated and
undifferentiated areas in a mixed thyroid cancer.
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Material and methods
Patients. A 74 year old female, with a history of non-functioning
long-standing thyroid goiter diagnosed approximately 20 years
before, was admitted to the Department of Endocrinology and
Metabolism in Poznan on May 2001 with a rapidly growing neck
mass, that had gradually enlarged over the previous three months.
The physical examination revealed a diffusely enlarged right thyroid
lobe with palpable nodules. Thyroid function tests gave normal
results. Ultrasonography of the neck revealed an enlarged right lobe
with a volume of 53 ml. It contained multiple nodules with a domi-
nant hypoechoic irregular nodule of 4.5 cm diameter. The left thy-
roid lobe had a volume of 6 ml. There were four enlarged (1-1.4cm)
cervical lymph nodes on the right side and no detectable lymph
nodes on the left side. Trachea X-ray showed the trachea displaced
to the patients left side. Chest X-ray was negative for metastatic dis-
ease. Fine needle aspiration biopsy was performed and the cytologi-
cal examination revealed colloidal nodule of the thyroid with no
signs of any malignancy. On June 2001 the patient was taken to the
surgery for a thyroidectomy. The intraoperative findings were an
enlarged right lobe with tracheal and surrounding tissues infiltration
and enlarged cervical lymph nodes. Total thyroidectomy, radical
neck lymph nodes dissection and tracheostomy were performed.
Pathology report confirmed the diagnosis of ATC. Two cervical
lymph nodes were removed with no cancer cells within. The patient
recovered from her surgery and was referred to our Department for
consideration of further therapy. On admission, serum thyrotropin
(TSH) level was 13.5 μU/ml (normal 0.20-4.2), serum thyroglobulin
((Tg) level was 56.5 ng/ml (normal 0-70 ng/ml) and serum calcitonin
level was undetectable (normal 0-10 pg/ml). Chest and abdominal
CT scan showed no signs of distant metastasis. Fiberoptic examina-
tion revealed a paralyzed right vocal cord. The histopathologic
examination, verified at our institution, revealed a coexistence of
anaplastic and follicular thyroid cancer (Fig. 1A). 
The decision was made to treat the patient with adjuvant exter-
nal radiotherapy, then she received a total dose of 51Gy. Acute tox-
icities included pharyngoesophagitis, but no chronic toxicity was
observed. She completed therapy on July 2001. Thyroid function
tests measured three months later, on levothyroxine (L-T4) substi-
tution therapy, were in the euthyroid range with TSH level of 0.57
mU/l, serum Tg level was undetectable (<3 ng/ml). The neck ultra-
sonography disclosed no significant abnormality. Tracheostomy
tube was removed on December 2002. The patient was followed up
on L-T4 treatment regularly with physical exams, serum Tg and
TSH levels, neck ultrasonography and chest X-ray. She continued
to be in complete remission more than 4.6 years after diagnosis. On
2006 during a next follow-up visit serum Tg measured on L-T4
treatment was found to be elevated (46 ng/l). After one month of
thyroxine withdrawal the patient was treated with 150 mCi (milli-
curies) of 131-I. The 1-week-postablation whole body scan dis-
closed 131-I uptake in thyroid remnants. There was no pathologi-
cal uptake outside the thyroid bed. A repeated thyroglobulin level
under suppression was obtained three months later, it was 26 ng/ml
suggesting a disease persistence. The patient is expected to be
admitted to our Department for further therapy.
Immunohistochemical techniques. Immunohistochemical staining
was performed on 4-6 μm thick paraffin-embedded sections accord-
ing to the avidin-biotin-peroxidase method. Sections of paraffin-
embedded tissue samples were immunostained for TTF1, Ki67, thy-
roglobulin, leucocyte common antigen (LCA) and cytokeratin
AE1/AE3 using monoclonal or polyclonal antibodies. The sections
were incubated with the primary antibody in "antibody diluent"
(DAKO) and goat anti-mouse or goat anti-rabbit EnVision-HRP-
enzyme conjugate was performed for 3 min each. The "highly sensi-
tive 3,3' diaminobenzidine plus" (DAB+) chromogen (from DAKO)
was used as substrate for the EnVision-HRP-enzymes. The slides
were coumterstained with hematoxilin and eosin. 
Results
Using mouse monoclonal anti-human antibodies we
investigated the expression of the thyroid transcription
factor 1 (TTF-1) in the follicular and anaplastic areas.
The expression of TTF-1 was found to be positive in the
nucleus of the follicular tumor cells (Fig. 1B) and nega-
tive effect was found in the nuclei of the anaplastic areas
(Fig. 1C). Thyroglobulin expression was negative in the
anaplastic areas contrary to the follicular areas (Fig.
1D,E). In order to eliminate non-Hodgkin's lymphomas
staining for leucocyte common antigen, LCA
(M070101, DAKO), was performed which was positive
only in the blood derived cells (Fig. 1F). Using two sec-
ond generation antibodies against proliferation marker,
Ki-67 (N1633330, DAKO), we investigated the cells
proliferative activity. The rate of tumor cells with nuclei
positive for Ki-67 in the anaplastic areas was 30 ± 5%
and, moreover, among the Ki-67 positive cells a number
of lymphocytes are seen as showing expression of the
Ki-67 proliferation cell antigen (Fig. 1G). The diagnosis
of the anaplastic thyroid carcinoma was also confirmed
by immunohistochemically verified coexpression of
mesenchymal vimentin (M072502, DAKO), and epithe-
lial cytokeratin AE1/AE3 (M351501, DAKO) markers
(Fig. 1H,I). 
Discussion 
ATC accounting 1.6% of all thyroid cancer is one of
the most aggressive and lethal solid tumors known to
affect humans. Very few anaplastic thyroid cancer
patients survive longer than a year, and report of long-
term survivors casts doubt on the validity of their diag-
nosis [5,6]. Passler and coworkers [7] found that irre-
spective of the surgical approach used, 5-year survival
rate ranges from 4% to 8%. It is essential to verify the
diagnosis histologically and immunohistochemically
because insular thyroid cancer, lymphomas, sarcomas,
and medullary thyroid cancer are occasionally con-
fused with anaplastic thyroid cancer. This is the first
report of TTF-1 and Ki-67 expression investigated in a
coexistent anaplastic and follicular thyroid cancer in a
patient with rare long-life survival. Zhang and cowork-
ers [8] investigated the expression of thyroid transcrip-
tion factor 1 in thyroid neoplastic tissues in different
degrees of differentiation and found that the localiza-
tion of this transcription factor was gradually
decreased corresponding to the progressive dedifferen-
tiation of thyroid tumors. In our case we observed a
positive expression of the TTF-1 in the follicular well
differentiated areas and negative expression in the
anaplastic undifferentiated (transformed?) areas,
which is in agreement with the data published by other
authors. 
On the other hand, Katoh and coworkers [9] inves-
tigated the proliferation marker Ki-67 in thyroid neo-
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plasms and showed that the highest ki-67 positive cell
rate was seen in anaplastic thyroid carcinomas and it
ranged between 12-70%. In our case the Ki-67 was 30
± 5% in the anaplastic areas, while it does not exceed
2% in the follicular areas. 
The coexistence of different histopathological
types of thyroid cancer within the same neoplastic
lesion is an unusual event. Wiseman et al. found that
the coexistence of ATC with well differentiated cancer
(WDC) ranged between 23% and 90%, respectively
[11]. These findings support the concept that many
ATCs might arise from preexisting or coexisting WDC
by malignant transformation [10-12]. In order to
understand the anaplastic transformation recent studies
have investigated the role of cell cycle regulators in
thyroid carcinomas (p21, p27, p57), which are compo-
nents of the Cip/Kip family. Tallini and coworkers [13]
thoroughly analyzed 90 thyroid carcinomas of follicu-
lar cell origin and found that low p27 expression and
high proliferative rate were associated with poor sur-
vival. Ito and coworkers [14] suggested that the down-
regulation of p57 protein is significantly related to the
dedifferentiation of thyroid carcinoma and increasing-
ly aggressive character of follicular carcinoma. Many
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Fig. 1. Micrographs illustrating histology and the studied immunohistochemical markers in mixed follicular and anaplastic thyroid tumor. 
A. Staining with hematoxylin and eosin shows follicular cancer in the lower left corner and anaplastic type in the upper right corner (origi-
nal magnification ×10); B. immunohistochemical demonstration of TT1 expression in a number of cell nuclei of follicular cancer while no
of the anaplastic cancer cells (C) shows reaction for TT1 (original magnification ×40); D. follicular cancer cells showing positive reaction
for thyreoglobulin but in the anaplastic area (E) the immunohistochemical reaction for the tyreoglobulin was negative (original magnifica-
tion ×30); F. in anaplastic area of tumor the LCA expression was limited to the blood derived cells and the reaction was lacking in anaplas-
tic cancer cells (original magnification ×20); G. marker of proliferating cells, Ki-67, was demonstrated immunohistochemically in the nuclei
of both the anaplastic cancer cell and blood derived lymphocytes (original magnification ×2x); H. anaplastic cancer cells shows cytoplasmic
expression of vimentin and (I) some cells of the anaplastic cancer showed expression of cytokeratins AE1/AE3 (original magnification ×30).
authors have recently emphasized the role of the TP53
gene product, the p53 protein, in the anaplastic tumor
development. Lam and others found that the loss of
p53 or the presence of abnormal p53 can be responsi-
ble for transformation of WDC to ATC [3,15]. Stoler
and coworkers [16] have noted that p53 alterations are
rarely found in cell lines of WDC. There-expression of
p53 in these cell lines has been shown to be associated
with reversal of some aspects of the anaplastic trans-
formation. These include restoration of chemosensitiv-
ity and radiosensitivity, inhibition of cellular prolifera-
tion, restoration of response to thyroid-stimulating
hormone, and re-expression of thyroid peroxidase
[16]. Because most of these data are gathered from
anaplastic cell lines in vitro, they have to be interpret-
ed with caution. 
Finally, it is necessary to consider the infiltration of
the anaplastic area by Ki-67 positive lymphocytes that
has been demonstrated in this report. The blood
derived cells showing expression of both, LCA and Ki-
67, we were able to recognize and document in
anaplastic area of the tumor. A correlation of the
inflammatory processes or infiltration by the cells
showing both of the above mentioned markers in thy-
roid tumors and disease-free survival has been report-
ed by Gupta and coworkers [17] especially, but not
only, in children and young adults. 
Summarizing our experience with this case and
the effects of immunostaining it seems conceivable to
suggest that in rapidly growing highly suspected thy-
roid masses the TTF-1 and Ki-67 could provides use-
ful information on the differentiation step of thyroid
tumor cells and may be helpful in discrimination
between well differentiated and undifferentiated
areas in a mixed thyroid tumor. Moreover, demon-
stration of the Ki-67 positive proliferating lympho-
cytes among the anaplastic tumor cells may indicate
an interference of immune system into the tumor pro-
gression. 
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